Metavia logo

Metavia Share Price (NASDAQ: MTVA)

$0.63

-0.02

(-3.08%)

Last updated on

Check the interactive Metavia Stock chart to analyse performance

Metavia Inc Key Stats

Check Metavia key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$0.65
Open
$0.64
Market Capitalization
$14.4M
Today's Volume
$33.2K
Revenue TTM
$0.0
EBITDA
$-28.9M
Earnings Per Share (EPS)
$-4.29
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-160.76%

Stock Returns calculator for Metavia Stock including INR - Dollar returns

The Metavia stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Metavia investment value today

Current value as on today

₹23,233

Returns

₹76,767

(-76.77%)

Returns from Metavia Stock

₹82,051 (-82.05%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Metavia Stock

6%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Metavia Stock from India on INDmoney has increased by 6% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Metavia Stock

Rating
Trend

Metavia Share Price Target

What analysts predicted

Upside of 2439.68%

Target:

$16.00

Current:

$0.63

Metavia share price target is $16.00, a slight Upside of 2439.68% compared to current price of $0.63 as per analysts' prediction.

Metavia Stock Insights

  • Price Movement

    In the last 6 months, MTVA stock has moved down by -55.7%
  • MTVA vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 152.4%
  • MTVA vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 116.0% return, outperforming this stock by 215.2%

Metavia Technicals Summary

Sell

Neutral

Buy

Metavia is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Metavia Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Metavia Inc logo
6.24%
-55.38%
-81.56%
-99.13%
-99.96%
Regeneron Pharmaceuticals, Inc. logo
3.92%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
2.49%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-15.42%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
11.08%
83.28%
75.87%
111.28%
242.25%

About Metavia Inc

MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Organization
Metavia
Employees
9
CEO
Mr. Heon Kim Hyung
Industry
Miscellaneous

Key Management of Metavia Inc

NameTitle
Mr. Heon Kim Hyung
CEO, President & Director
Mr. Marshall H. Woodworth
Chief Financial Officer
Dr. Mi-Kyung Kim
Chief Scientific Officer
Mr. Robert Homolka
Senior Vice President of Clinical Operations
Dr. W. Christopher Fang M.D.
Consulting Chief Medical Officer & Advisor
Mr. Michael Pine
Senior Vice President of Business Development Advisor

Important FAQs about investing in MTVA Stock from India :

What is Metavia share price today?

Metavia share price today is $0.63 as on at the close of the market. Metavia share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Metavia share?

Metavia share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Metavia stock price today i.e. is closed at $0.63, lower by 77.09% versus the 52 week high.

How to invest in Metavia Stock (MTVA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Metavia on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Metavia Shares that will get you 2.3810 shares as per Metavia share price of $0.63 per share as on August 30, 2025 at 1:27 am IST.

What is the minimum amount required to buy Metavia Stock (MTVA) from India?

Indian investors can start investing in Metavia (MTVA) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Metavia stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Metavia share’s latest price of $0.63 as on August 30, 2025 at 1:27 am IST, you will get 15.8730 shares of Metavia. Learn more about fractional shares .

What are the returns that Metavia has given to Indian investors in the last 5 years?

Metavia stock has given -99.96% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?